Gemifloxacin
A fluoroquinolone antibiotic used to treat respiratory tract infections including community-acquired pneumonia and acute bacterial exacerbation of chronic bronchitis. It works by inhibiting DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication and repair. It should be used cautiously as fluoroquinolones carry risks of tendon damage and nerve-related side effects.
Masse moléculaire
389,4000 g/mol
LogP
-0,70
TPSA
121,00 Ų
Règle des 5 de Lipinski
Conforme
Aires thérapeutiques
Mécanisme d'action
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. This leads to breakage of bacterial chromosomal DNA and rapid cell death.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. This leads to breakage of bacterial chromosomal DNA and rapid cell death.
Structure 2D
Cite this structure
Embed this structure
SMILES
CO/N=C1\CN(c2nc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)CC1CN
InChI
InChI=1S/C18H20FN5O4/c1-28-22-14-8-23(6-9(14)5-20)17-13(19)4-11-15(25)12(18(26)27)7-24(10-2-3-10)16(11)21-17/h4,7,9-10H,2-3,5-6,8,20H2,1H3,(H,26,27)/b22-14+
Molecular Formula
C18H20FN5O4
HBD / HBA
2 / 10
Liaisons Rotatives
5
Atomes Lourds
28
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
A fluoroquinolone antibiotic used to treat respiratory tract infections including community-acquired pneumonia and acute bacterial exacerbation of chronic bronchitis. It works by inhibiting DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication and repair. It should be used cautiously as fluoroquinolones carry risks of tendon damage and nerve-related side effects.
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. This leads to breakage of bacterial chromosomal DNA and rapid cell death.
Yes, Gemifloxacin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL430. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 9571107. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="gemifloxacin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/gemifloxacin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/gemifloxacin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/gemifloxacin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="gemifloxacin"></drugfyi-drug>